India, Aug. 7 -- Prof. Hridayesh Prakash, Deputy Director, Amity Centre for Translational Research, Amity University Noida, along with partnering national labs, have pioneered a novel host directed approach to combat Tuberculosis (TB), particularly drug-resistant TB (MDR-TB), by developing TB specific Neutraceutical for controlling Tuberculosis , the first of its kind in the country, which has been officially approved by regulatory bodies. This innovation is a milestone and caters to the Government's TB Free Mission- 2025. Explaining about his innovation, Prof. Prakash , said, "ATLS-PA 2021, comprising of two molecules L-serine and Palmitoyl Co-A administered at two different time points, is an innovative anti-tubercular adjunct therapy des...